Neurogene (NGNE) to Release Earnings on Friday

Key Points

• Neurogene is set to announce its Q2 2025 earnings results on August 8th, expecting to report losses of ($1.15) per share.
• The company's stock has seen a significant decline of 44%, and analysts project a consensus price target of $46.17 with a rating of "Moderate Buy".
• Insider transactions reveal that Stuart Cobb sold nearly 7,000 shares recently, indicating a 24.63% decrease in his position.

Neurogene (NASDAQ:NGNE - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Friday, August 8th. Analysts expect the company to announce earnings of ($1.15) per share for the quarter.

Neurogene (NASDAQ:NGNE - Get Free Report) last released its quarterly earnings data on Friday, May 9th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($1.05) by ($0.03). On average, analysts expect Neurogene to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Neurogene Stock Performance

Shares of NGNE traded up $0.01 during midday trading on Friday, hitting $21.78. 125,828 shares of the company traded hands, compared to its average volume of 127,119. The firm has a 50 day moving average of $20.02 and a 200-day moving average of $16.96. Neurogene has a 52 week low of $6.88 and a 52 week high of $74.49. The stock has a market cap of $310.63 million, a price-to-earnings ratio of -5.01 and a beta of 1.51.

Insiders Place Their Bets

In related news, insider Stuart Cobb sold 6,797 shares of the stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $15.15, for a total value of $102,974.55. Following the sale, the insider directly owned 20,794 shares of the company's stock, valued at $315,029.10. This represents a 24.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 11.64% of the stock is owned by company insiders.

Institutional Trading of Neurogene

An institutional investor recently raised its position in Neurogene stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Neurogene Inc. (NASDAQ:NGNE - Free Report) by 17.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,983 shares of the company's stock after purchasing an additional 1,059 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.'s holdings in Neurogene were worth $82,000 as of its most recent SEC filing. 52.37% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

NGNE has been the subject of several research reports. Craig Hallum initiated coverage on shares of Neurogene in a report on Tuesday, June 17th. They set a "buy" rating and a $50.00 price objective for the company. Robert W. Baird downgraded shares of Neurogene from an "outperform" rating to a "neutral" rating and lowered their price target for the company from $38.00 to $24.00 in a report on Friday, May 16th. HC Wainwright lowered their price target on shares of Neurogene from $50.00 to $45.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. Baird R W downgraded shares of Neurogene from a "strong-buy" rating to a "hold" rating in a report on Friday, May 16th. Finally, BMO Capital Markets reaffirmed an "outperform" rating and issued a $26.00 price target (up previously from $22.00) on shares of Neurogene in a report on Thursday, June 12th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, Neurogene currently has an average rating of "Moderate Buy" and a consensus target price of $46.17.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.